ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Fatal Complications inJournal of fungi (Basel, Switzerland) · 2025Article
- A Review of Current Insights in Fungal Endocarditis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAmphotericin B-based treatment has been the cornerstone of Candida infective endocarditis (CIE) treatment, but recent guidelines also recommend echinocandins. However, there are limited outcome data. The few studies performed report differing results. Our aim in this study was to compare the outcome with echinocandins to those of other antifungal strategies.
methodsA CIE cohort was derived from the Swedish Registry of Infective Endocarditis for 1995-2019. In-hospital mortality or relapse was considered treatment failure.
results51 episodes in 38 patients were treated with echinocandins (n = 21), amphotericin B-based therapy (n = 22), or azoles (n = 8). The proportions of treatment failure were 32%, 38%, and 62%, respectively (P = .35). Patients who received echinocandins were older and had a higher burden of comorbidities. The overall 1-year mortality rate from index hospitalization was 26%, with no significant differences between backbone therapies (P = .18). Because Candida parapsilosis IE was not treated with echinocandins, a subgroup analysis was performed of 33 episodes with C. non-parapsilosis that showed no significant differences between backbone therapies (P = .33). In a subgroup analysis of episodes treated with amphotericin B-based therapy, treatment failure was seen in 54% of 13 episodes caused by C. parapsilosis and 12% of 8 episodes caused by C. non-parapsilosis (P = .10).
conclusionsNo differences in in-hospital mortality, relapse rate, or 1-year mortality were seen in patients with echinocandin-based therapy compared with other CIE regimens, despite risk factors in the echinocandin group that would be expected to negatively bias outcome. Candida parapsilosis CIE appears to pose specific challenges in terms of optimal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.